Loading...
NPI 1285677534 · Honolulu, HI · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Longs Drug Stores California LLC is a community/retail pharmacy provider located in Honolulu, Hawaii. This profile covers 10 Medicare and 16 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Longs Drug Stores California LLC |
| Address | 2470 S King St |
| City | Honolulu |
| State | HI |
| ZIP | 96826 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | June 14, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $385K |
| Medicaid | $135.1K |
Business profile and service mix: LONGS DRUG STORES CALIFORNIA LLC is registered as a Community/Retail Pharmacy and its claim mix strongly reflects point‑of‑care pharmacy services rather than procedural care. The Medicare and Medicaid top codes are dominated by vaccine administration and COVID testing products (notably 91320, 90480, 90694, and K1034), indicating the operation primarily provides immunizations and high-volume COVID testing/dispensing services at retail locations.
Medicare revenue concentration: The provider’s top 3 Medicare codes (91320, K1034, 90480) account for 70.5% of its total Medicare revenue, signaling a high concentration of Medicare receipts in vaccine and COVID‑related services. The single largest Medicare line is 91320 (32.0% of Medicare revenue, $122.1K), followed by K1034 (27.8%, $106K) and 90480 (10.7%, $41K), so Medicare performance is particularly sensitive to demand and reimbursement for these codes.
Medicaid revenue concentration: On the Medicaid side the top 3 codes (91320, 0002A, 90471) account for 42.1% of total Medicaid revenue, showing a more diversified revenue mix across additional vaccine administration and related CPT/HCPCS codes. The largest Medicaid single code is again 91320 ($25.9K, 19.0% of Medicaid revenue), but a broader set of A‑series and vaccine administration codes contribute meaningfully to the Medicaid book.
Payer mix and scale: Medicare revenue ($385K) materially exceeds Medicaid revenue ($135.1K), so the entity’s enterprise scale and reimbursement exposure is weighted toward Medicare. Both payers are active, but Medicare represents the larger portion of lifetime government payer receipts on file.
Competitive standing — Medicare: For key Medicare codes the provider ranks high in national percentile placement for vaccine and test activity: 91320 ranks #76 of 27083 providers nationally (100th percentile) and K1034 ranks #322 of 30143 (99th percentile), while 90480 ranks #152 of 46950 (100th percentile). These placements indicate the pharmacy bills at the upper percentiles nationally for those specific vaccination and COVID testing codes, even where narrative notes characterize the volumes as typical for the code.
Competitive standing — Medicaid (in‑state): Within Hawaii the provider is competitively prominent on several Medicaid codes: 91320 ranks #2 of 19 in-state (94th percentile) and 90661 ranks #1 of 37 in-state (100th percentile; notably above typical state volume). This suggests the pharmacy is one of the larger in‑state dispensers/administrators for selected vaccine products under Medicaid.
Statistical outliers and unusual billing signals: Certain codes show elevated in‑peer placement or reporting patterns that stand out in the provided labels. Medicare code 0121A is annotated as notably above typical national volume (rank #19 of 713, 97th percentile), and Medicaid code 90661 is noted as notably above typical state volume (rank #1 of 37, 100th percentile), while S9430 shows 132 Medicaid claims with $0 revenue (rank #6 of 33 in-state), indicating claims reported without associated paid revenue.
Tenure and operational stability: The provider’s NPI was enumerated on 2006-06-14 (~20 years ago), indicating long-standing participation in Medicare/Medicaid billing. That tenure, combined with consistently high-percentile placement on vaccine and testing codes, supports the characterization of an established retail pharmacy offering immunization and COVID testing services over a sustained period.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 950 | $130 | $122.1K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 9,640 | $10 | $106K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 950 | $40 | $41K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 500 | $80 | $37.2K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 80 | $280 | $22.4K |
| G0008 | Administration of influenza virus vaccine | 660 | $30 | $20.4K |
| 0124A | N/A | 430 | $40 | $18.6K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 150 | $70 | $10.9K |
| 0121A | N/A | 50 | $40 | $2.3K |
| G0009 | Administration of pneumococcal vaccine | 80 | $10 | $920 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 250 | $100 | $25.9K |
| 0002A | N/A | 440 | $40 | $17.1K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 1,300 | $10 | $14.3K |
| 0054A | N/A | 340 | $40 | $13.8K |
| 0001A | N/A | 420 | $30 | $13.3K |
| 0004A | N/A | 360 | $40 | $13.2K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 260 | $40 | $10.1K |
| 0124A | N/A | 250 | $40 | $10K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 560 | $20 | $9.4K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 90 | $30 | $2.4K |
Showing 1–10 of 16
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
16 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90472 | This code represents each injection of a vaccine after the first; list this code in addition to the code for the first injection. | 27 | 50 | 50 | $40 | $33.1K |
| 0002A | N/A | 16 | 70 | 160 | $40 | $20.8K |
| 0001A | N/A | 16 | 80 | 140 | $30 | $18.4K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 23 | 230 | 140 | $20 | $16.1K |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 2 | 20 | 30 | $120 | $12.1K |
| 0004A | N/A | 6 | 50 | 50 | $30 | $5.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 28 | 180 | 120 | $10 | $4.7K |
| 0054A | N/A | 5 | 40 | 80 | $30 | $4.5K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 4 | 60 | 50 | $30 | $2.8K |
| 90750 | The provider injects an adjuvanted vaccine into a muscle to protect the patient against varicella zoster infection. | 4 | 10 | 10 | $70 | $2.8K |
Showing 1–10 of 16
Other providers in the same ZIP code as Longs Drug Stores California LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.